Fulcrum therapeutics reports recent business highlights and first quarter 2021 financial results

– on track to present data from phase 2b redux4 trial with losmapimod in facioscapulohumeral muscular dystrophy (fshd) at virtual fshd international research congress in june 2021 –

FULC Ratings Summary

FULC Quant Ranking